Search company, investor...
Clovis Oncology company logo

Clovis Oncology

Founded Year




Total Raised


Market Cap


About Clovis Oncology

Clovis Oncology is developing cancer treatments for certain patients who have metastatic pancreatic cancer, non-small cell lung cancer, and various solid tumors. The Company is focused on licensing or acquiring rights to oncology compounds in all stages of clinical development.

Headquarters Location

5500 Flatiron Parkway

Boulder, Colorado, 80301,

United States


Missing: Clovis Oncology's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Clovis Oncology's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Clovis Oncology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Clovis Oncology is included in 1 Expert Collection, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Clovis Oncology Patents

Clovis Oncology has filed 8 patents.

The 3 most popular patent topics include:

  • Antineoplastic drugs
  • Alkylating antineoplastic agents
  • Cancer treatments
patents chart

Application Date

Grant Date


Related Topics




Dosage forms, Pharmaceutical industry, Fluoroarenes, Antineoplastic drugs, Drug delivery devices


Application Date


Grant Date



Related Topics

Dosage forms, Pharmaceutical industry, Fluoroarenes, Antineoplastic drugs, Drug delivery devices



Latest Clovis Oncology News

Clovis files to abandon leases in California

Jan 5, 2023

Clovis Oncology Inc., the Boulder-based drug developer that defaulted on a loan and was forced to file for protection under Chapter 11 bankruptcy, has petitioned the court to permit it to shed leases on real estate that it no longer needs for its operation.

Clovis Oncology Frequently Asked Questions (FAQ)

  • When was Clovis Oncology founded?

    Clovis Oncology was founded in 2009.

  • Where is Clovis Oncology's headquarters?

    Clovis Oncology's headquarters is located at 5500 Flatiron Parkway, Boulder.

  • What is Clovis Oncology's latest funding round?

    Clovis Oncology's latest funding round is PIPE.

  • How much did Clovis Oncology raise?

    Clovis Oncology raised a total of $145M.

  • Who are the investors of Clovis Oncology?

    Investors of Clovis Oncology include Citadel, Frazier Healthcare Partners, Versant Ventures, Domain Associates, Aberdare Ventures and 5 more.

  • Who are Clovis Oncology's competitors?

    Competitors of Clovis Oncology include Arena Pharmaceuticals, Crown Bioscience, SpiroGen, Cytochroma, Novexel and 12 more.

Compare Clovis Oncology to Competitors

QuatRx Pharmaceuticals

QuatRx Pharmaceuticals Company is focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas. In addition to QRX-431, QuatRx currently has three product candidates in clinical development. QuatRx


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Aqumen Biopharmaceuticals

The company's current portfolio of compounds and technologies in the development pipeline includes: i) A0001, Ophthalmic Dye for Retinal Surgery ii) A0003, treatments for Age-related Macular Degeneration (AMD). and iii)A0006 . Company is in negotiations to acquire rights to a Phase II program by year end 2007. The following diagram summarizes the important existing and anticipated clinical development milestones for each of the programs as they relate to their respective targeted applications:


Cryptopharma is a Company focused on the discovery and development of anti-inflammatory therapeutic agents for treatment of pulmonary diseases. The company's initial focus is on the development of CP92, a treatment of Cystic Fibrosis. Second generation compounds are in development with the potential to treat other inflammatory conditions including asthma and chronic obstructive pulmonary disease (COPD). See

NanoMedex Pharmaceuticals

NanoMedex uses patented formulation strategies to dissolve drugs in water that are only soluble in fats or lipids. Once dissolved in water, these drugs can be administrated intravenously. In hospitals, intravenous administration is preferred by older patients to eliminate swallowing, by physicians to increase certainty that the correct drug dose is given, and by health care providers to ensure that Medicare reimburses 100 percent of costs (versus 50 percent for oral administration).


Phytomedics is a biopharmaceutical company based in New Jersey with a broad portfolio of novel compounds for chronic diseases. The lead compound is in clinical development and has shown extraordinary results in clinical trials for the treatment of auto immune disorders like rheumatoid arthritis. The company's platform technology is the basis of their large portfolio of novel therapeutic compounds.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.